RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oncolys Biopharma Stock

Oncolys Biopharma Equity 2024

Oncolys Biopharma Equity

1.47 B JPY

Ticker

4588.T

ISIN

JP3202170001

WKN

A1W94N

In 2024, Oncolys Biopharma's equity was 1.47 B JPY, a -31.73% increase from the 2.16 B JPY equity in the previous year.

Oncolys Biopharma Aktienanalyse

What does Oncolys Biopharma do?

Oncolys Biopharma Inc. is a company specialized in the development of innovative medications for the treatment of cancer. The company was founded in 2001 in Tokyo, Japan and has become a key player in the biotechnology industry over the years. The company's business model is based on the development of innovative therapies for cancer patients. It works closely with leading scientists and researchers to advance its research projects, focusing on the discovery and development of new compounds based on the OncoTherad virus. Oncolys Biopharma Inc. offers a wide range of products and services, including cancer medications based on the OncoTherad virus, as well as diagnostic and monitoring tools for hospitals and medical facilities. It has various divisions that encompass research and development, manufacturing, and distribution and marketing of cancer medications and diagnostic systems. The company is committed to expanding its research and development activities to develop new medications for different types of cancer. In addition to cancer medications, Oncolys Biopharma Inc. is also working on developing therapies for other serious illnesses such as viral diseases. The company has a promising pipeline of new medications being tested in various clinical trials. Overall, Oncolys Biopharma Inc. is a key player in the biotechnology industry specializing in the development of innovative therapies for cancer and viral diseases. The company has built an excellent reputation over the years and is committed to continuing its growth and expansion. Oncolys Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Oncolys Biopharma's Equity

Oncolys Biopharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Oncolys Biopharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Oncolys Biopharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Oncolys Biopharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Oncolys Biopharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Oncolys Biopharma stock

What is the equity of Oncolys Biopharma this year?

Oncolys Biopharma has equity of 1.47 B JPY this year.

What was the equity of Oncolys Biopharma compared to the previous year?

The equity of Oncolys Biopharma has increased/decreased by -31.73% decreased compared to the previous year.

What impact does a high equity have on investors of Oncolys Biopharma?

A high equity is advantageous for investors of Oncolys Biopharma as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Oncolys Biopharma?

A low equity can be a risk for investors of Oncolys Biopharma, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Oncolys Biopharma affect the company?

An increase in equity of Oncolys Biopharma can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Oncolys Biopharma affect the company?

A reduction in equity of Oncolys Biopharma can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Oncolys Biopharma?

Some factors that can affect the equity of Oncolys Biopharma include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Oncolys Biopharma so important for investors?

The equity of Oncolys Biopharma is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Oncolys Biopharma take to change the equity?

To change equity, Oncolys Biopharma can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Oncolys Biopharma pay?

Over the past 12 months, Oncolys Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncolys Biopharma is expected to pay a dividend of 0 JPY.

What is the dividend yield of Oncolys Biopharma?

The current dividend yield of Oncolys Biopharma is .

When does Oncolys Biopharma pay dividends?

Oncolys Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncolys Biopharma?

Oncolys Biopharma paid dividends every year for the past 0 years.

What is the dividend of Oncolys Biopharma?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncolys Biopharma located?

Oncolys Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncolys Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncolys Biopharma from 9/25/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 9/25/2024.

When did Oncolys Biopharma pay the last dividend?

The last dividend was paid out on 9/25/2024.

What was the dividend of Oncolys Biopharma in the year 2023?

In the year 2023, Oncolys Biopharma distributed 0 JPY as dividends.

In which currency does Oncolys Biopharma pay out the dividend?

The dividends of Oncolys Biopharma are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oncolys Biopharma

Our stock analysis for Oncolys Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncolys Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.